Shaping the Future of Healthcare Innovation
Forward-Acting for Positive Change in Healthcare
Amidst the deindustrialization of Europe’s generics sector in recent years, Greece introduced significant investment incentives, prompting DEMO Pharmaceuticals to launch a robust investment program in 2021 valued at over €350 million.
The six-year investment plan, which is set to be completed by 2027, is designed and executed with a clear focus on our ongoing commitment to innovation and reliability. The projects within this plan represent 25% of the total investments made by the Greek pharmaceutical industry. These efforts will focus on two key areas: conventional technology, encompassing the research, development, and production of chemical APIs and medicines, while also marking our entry into the biotechnology sector through the R&D and production of biological APIs and medicines.
Through these investments, DEMO achieves vertical integration and gains the capability to produce all injectable pharmaceutical forms and categories currently available. This ensures domestic self-sufficiency and security of supply of critical medicines not only for Greece but for Europe as a whole.
Investment Pillars
Increase in Production Capacity and Upgrade of Manufacturing Facilities at Kryoneri
As part of its ongoing investments in the primary manufacturing facility in Kryoneri, Attica, DEMO made significant strides to enhance both equipment and infrastructure. The company successfully implemented a range of projects aimed at increasing production capacity and upgrading its manufacturing facilities. Specifically, the key pillars of the completed projects are as follows:
Remaining true to its strategy of investing in the production of pharmaceutical raw materials in Greece, DEMO continued the implementation of its new industrial complex in the Tripoli Industrial Area (V.I.P.E.). A key requirement in this direction was the utilization of the expertise from the Research and Development Center in Thessaloniki, which aims to develop five active pharmaceutical ingredients (APIs) annually, and has now been fully operational.
In parallel with the ongoing development of the necessary building and electromechanical infrastructure at the Tripoli V.I.P.E., the company also proceeded with the procurement of advanced production and packaging equipment. These efforts represent a significant step in enhancing DEMO’s capacity for the development and manufacturing of high-quality pharmaceutical raw materials, contributing to the growth of the pharmaceutical industry in Greece.
Research and Development (R&D) is at the core of DEMO’s operations. For over 15 years, the company has consistently invested in its research activities, ensuring the steady growth of its product portfolio and expanding its presence with new licenses.
As part of its investment plan, DEMO created a Research and Development Center in Thessaloniki, which was inaugurated in mid-2022. The Center spans over 2,400 sq.m. and houses 13 laboratories for two dedicated research teams: the chemical molecules team and the active pharmaceutical ingredients (API) team.
This significant investment in R&D underscores DEMO’s commitment to advancing the development of high-quality finished products and further enhancing its innovation capabilities.
The Biotechnology sector remains of paramount importance for DEMO, which has accelerated investments related to research and production in order to meet the increasing prevalence of biological medicines in the healthcare sector.
The Biotechnology Research and Development Laboratory, equipped with the necessary laboratory and pilot equipments dedicated to developing the necessary expertise and conducting clinical trials through laboratory pilot batches, paving the way for the operation of the Biosimilars Production Facility in Agios Stefanos.
Το έργο υλοποιείται στο πλαίσιο του Εθνικού Σχεδίου Ανάκαμψης και Ανθεκτικότητας «Ελλάδα 2.0», με τη χρηματοδότηση της Ευρωπαϊκής Ένωσης – NextGenerationEU